PWM
CBIO

Perigon Wealth Management’s Crescent Biopharma CBIO Stock Holding History

Perigon Wealth Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-1
Closed -$2K – 388
2018
Q1 		$2K Hold
1
– – ﹤0.01% 593
2017
Q4 		$2K Hold
1
– – ﹤0.01% 571
2017
Q3 		$1K Buy
+1
New +$1.17K ﹤0.01% 618

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perigon Wealth Management's CBIO Position: Q2 2018 in Review

Perigon Wealth Management sold out of Crescent Biopharma (CBIO) in Q2 2018, closing a stake of 1 share — an estimated $2K sold.

Perigon Wealth Management first reported a position in CBIO in Q3 2017 and held it in 3 quarters. The position peaked at $2K in Q1 2018. 84 funds tracked by Wall St. Rank hold CBIO as of Q2 2018.

  • Perigon Wealth Management reported no remaining Crescent Biopharma position as of Q2 2018 after selling out during the quarter.
  • Perigon Wealth Management sold 1 Crescent Biopharma share in Q2 2018, an estimated $2K.
  • Perigon Wealth Management first reported a position in Crescent Biopharma in Q3 2017 and held it in 3 quarters.
  • Perigon Wealth Management's Crescent Biopharma position peaked at $2K in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2018.

Based on Perigon Wealth Management's 13F filing for Q2 2018, filed 7 Aug 2018.